Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis.: Preliminary results in 24 patients

被引:74
|
作者
Elias, D
Sideris, L
Pocard, M
Edè, C
Ben Hassouna, D
Ducreux, M
Boige, V
Côté, JF
Lasser, P
机构
[1] Inst Gustave Roussy, Dept Surg Oncol, Villejuif, France
[2] Inst Gustave Roussy, Intens Care Unit, Villejuif, France
[3] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[4] Inst Gustave Roussy, Dept Pathol, Villejuif, France
关键词
colorectal; intraperitoneal chemohyperthermia; oxaliplatin; peritoneal carcinomatosis; surgery;
D O I
10.1093/annonc/mdh186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The complete resection of macroscopic colorectal peritoneal carcinomatosis (PC), followed by intraoperative intraperitoneal chemohyperthermia (IPCH) to treat residual microscopic disease, leads to cure in some patients. We report preliminary results on survival in a phase II study using oxaliplatin (LOHP). Patients and methods: Twenty-four patients with macroscopic colorectal PC underwent complete resection of the PC followed by IPCH with LOHP performed in an open abdominal cavity. The dose of LOHP was 460 mg/m(2) in 21/m(2), during 30 min at 43degreesC, at a flow rate of 21/min. During the hour preceding IPCH, they received an intravenous administration of 5-fluorouracil (400 mg/m(2)) and leucovorin (20 mg/m(2)). Results: Mean peritoneal tumoral extension (Sugarbaker's Index) was 16.9 +/- 9.5, median operative duration was 490 min and median blood loss was 965 ml. There were two postoperative deaths (8%) by intracerebral hemorrhage, and morbidity rate was 41.6%. Minimal follow-up was 18 months and median follow-up was 27.4 months (range 18.3-49.6). At 1, 2 and 3 years, overall survival rates were 83%, 74% and 65%, and disease-free survival rates were 70%, 50% and 50%, respectively. Only 32% of the 22 postoperative living patients presented a peritoneal recurrence. A peritoneal index >24 influenced survival, with a 17% recurrence rate at 2 years versus 63% when it was <24 (P = 0.005). Conclusion: This new modality of treatment, when feasible, gives encouraging preliminary results, with a promising 3-year survival rate of 65%.
引用
收藏
页码:781 / 785
页数:5
相关论文
共 50 条
  • [31] Cytoreductive surgery (CRS) combined with intraperitoneal chemohyperthermia (IPCH) in the treatment of peritoneal carcinomatosis (PC): The exemple of colorectal cancer
    Gilly, Francois N.
    Beaujard, Annie C.
    Francois, Yves
    Cotte, Eddy
    Lifante, Jean C.
    Glehen, Olivier
    ANNALS OF ONCOLOGY, 2006, 17 : 29 - 29
  • [32] Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer
    Zanon, C
    Clara, R
    Chiappino, I
    Bortolini, M
    Cornaglia, S
    Simone, P
    Bruno, F
    De Riu, L
    Airoldi, M
    Pedani, F
    WORLD JOURNAL OF SURGERY, 2004, 28 (10) : 1040 - 1045
  • [33] Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer
    Alhumaid, Moayad
    Sait, Salma
    Fallatah, Emad
    AlSayegh, Nasser
    Farsi, Ali
    Nassif, Mohammed
    Farsi, Nada J.
    Akeel, Nouf
    Samkari, Ali
    Shabkah, Alaa A.
    Trabulsi, Nora
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [34] Bidirectional intraperitoneal chemotherapy with oxaliplatin in the context of CRS and HIPEC in patients with peritoneal carcinomatosis
    Glockzin, G.
    Schlitt, H. J.
    Piso, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [35] Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Recurrent Peritoneal Carcinomatosis from Ovarian Cancer
    Claudio Zanon
    Renzo Clara
    Isabella Chiappino
    Massimiliano Bortolini
    Silvia Cornaglia
    Paolo Simone
    Francesco Bruno
    Leonarda De Riu
    Mario Airoldi
    Fulvia Pedani
    World Journal of Surgery, 2004, 28 : 1040 - 1045
  • [36] Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis
    Chandler, Christopher S.
    Bell, Meghan M.
    Chung, Sebastian K.
    Veach, Darren R.
    Fung, Edward K.
    Punzalan, Blesida
    Vargas, Daniela Burnes
    Patel, Mitesh
    Xu, Hong
    Guo, Hong-fen
    Santich, Brian H.
    Zanzonico, Pat B.
    Monette, Sebastien
    Nash, Garrett M.
    Cercek, Andrea
    Jungbluth, Achim
    Pandit-Taskar, Neeta
    Cheung, Nai Kong, V
    Larson, Steven M.
    Cheal, Sarah M.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (01) : 125 - 137
  • [37] Cytoreductive surgery plus intraperitoneal chemo-hyperthermia in patients with peritoneal carcinomatosis. A single institution experience
    Farre, J
    Rebollo, J
    Molina, M
    Sureda, M
    Martin, M
    Magarzo, J
    Brugarolas, A
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 62 - 63
  • [38] Concurrent hyperthermic intraperitoneal chemotherapy and intraoperative radiotherapy with cytoreductive surgery in patients with rectal cancer with peritoneal carcinomatosis.
    Arabi, Tarek
    Alaswad, Marwan
    Sabbah, Belal Nedal
    Al Otry, Abdullah
    Hejazi, Alwalid
    Ismail, Aya
    Jaamour, Heba
    Alhosainy, Ziad
    Al Homoud, Samar
    Azzam, Ayman
    Amin, Tarek
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center
    Faviana, Pinuccia
    Boldrini, Laura
    Musco, Barbara
    Ferrari, Mauro
    Greco, Alfonso
    Fornaro, Lorenzo
    Masi, Gianluca
    Forfori, Francesco
    Ricci, Sergio
    Brogi, Augusto
    Basolo, Fulvio
    Falcone, Alfredo
    Gadducci, Angelo
    Lippolis, Piero Vincenzo
    IN VIVO, 2020, 34 (04): : 2061 - 2066
  • [40] RESULTS OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY AND CYTOREDUCTIVE SURGERY FOR PERITONEAL CARCINOMATOSIS OF COLORECTAL ORIGIN
    Merayo Alvarez, M.
    Turienzo Santos, E.
    Garcia Munar, M.
    Cifrian Canales, I.
    Rodicio Miravalles, J. L.
    Moreno Gijon, M.
    Sanz Alvarez, L.
    BRITISH JOURNAL OF SURGERY, 2021, 108 : 17 - 17